This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Hang on a second…

This CME Activity has expired and is no longer available for credit.

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

The Rejection Guessing Game: Individualizing Calcineurin Inhibitor (CNI) Therapy to Manage Rejection in Renal Transplantation Patients—Maintaining Transplant Integrity: Side Effects of and Adherence to CNIs

The Rejection Guessing Game: Individualizing Calcineurin Inhibitor (CNI) Therapy to Manage Rejection in Renal Transplantation Patients—Maintaining Transplant Integrity: Side Effects of and Adherence to CNIs

Format

Clinical Review

Time to Complete

30 minutes

Released

May 17, 2016

Expires

May 16, 2017
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM
0.50 / CE for Nurses
0.50 / CE for Nurse Practitioners
0.50 / CE for Pharmacists (0.05 CEUs)

Accredited Provider



Provided by Advancing Knowledge in Healthcare (AKH) Inc.

Commercial Supporter

This activity is supported by an educational grant from Astellas Pharma Global Development Inc.

In Collaboration With

This activity was produced in collaboration with the American Society of Transplant Surgeons (ASTS).

Program Description

The KDIGO guidelines recommend continued use of calcineurin inhibitors (CNIs) in the short and long term following renal transplant. More than 85% of kidney transplant patients take tacrolimus for maintenance. However, there is the potential for side effects with tacrolimus treatment, particularly increased neurotoxicity and GI side effects as well as an increased risk for new-onset diabetes. As a result of side effects, adherence to CNIs can be problematic, further compounding patient risk for transplant rejection. This presentation focuses on the prevention and management of side effects associated with CNI therapy and looks at measures to improve patient adherence to CNI therapy in the post-transplant setting.

Intended Audience

This activity is intended for nephrologists, transplant surgeons, nurses, nurse practitioners, pharmacists and other members of interprofessional transplant teams with a focus on kidney transplants.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

  • Employ strategies to manage the side effects of the various CNI therapies while maintaining transplant integrity
  • Identify additional issues that relate to transplant failure, such as biomarkers and medication regimen adherence

Conflict Of Interest Disclosure Policy

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc., Advancing Knowledge in Healthcare, planners and reviewers have no relevant financial relationships to disclose.

Faculty

Alexander C. Wiseman, MD, FACP
Professor of Medicine, Division of Renal Diseases and Hypertension
Medical Director, Kidney and Pancreas Transplant Programs
University of Colorado School of Medicine
Aurora, CO

Dr Wiseman had disclosed the following relevant financial relationships:
Consultant: Astellas Pharma US, Inc., Merck & Co., Inc., Veloxis Pharmaceuticals
Contracted Research: Bristol-Myers Squibb, Chimerix, Novartis, Oxford Immunotec, Inc.

Accredited Provider Disclosures/Publishing Staff Disclosures

STAFF/REVIEWERS
Tara Hun-Dorris, MMC, ELS
, Medical Writer/Interviewer, has disclosed the following relevant financial relationships:
Consultant- F. Hoffman La Roche Ltd

Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner; Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner; and Dorothy A. Duffy, B.S. Pharmacy, Pharmacy Reviewer, disclose no financial relationships with pharmaceutical or medical product manufacturers.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education.

Designation Statement

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME.

Credit

0.50

Type

CE for Nurses

Accreditation Statement

AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

This activity is awarded 0.50 Contact Hours.

Credit

0.50

Type

CE for Nurse Practitioners

Accreditation Statement

AKH, Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number: 030803.

Designation Statement

This program is accredited for 0.50 contact hour(s). Program ID #21613.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard

Credit

0.50

Type

CE for Pharmacists

Accreditation Statement

AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge- based activity for 0.50 contact hour(s) (0.05 CEUs). UAN 0077-0000-16-042-H04-P. Initial Release Date: May 6, 2016

Disclosure of Unlabeled Use

This educational activity will include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time. You must participate in the entire activity to receive credit.

To fully understand and translate learning, AKH suggests the following methods of active learning for this activity:

  • Develop a matrix to classify the at risk patients and appropriate treatment therapy
  • List situations where the different treatment options may be advantageous
  • Explore the bibliography and note references to review at a later date.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Add to Queue